Pesquisar
argenx SE
ARGXAdicionar à lista de desejos
852.500USD
-0.900-0.11%
Fechamento 06/24, 16:00（ET）Cotações atrasadas em 15 min
52.76BValor de mercado
35.23P/L TTM
Mais detalhes de argenx SE Empresa
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Informações de argenx SE
Código da empresaARGX
Nome da Empresaargenx SE
Data de listagemJul 10, 2014
CEOvan Hauwermeiren (Tim)
Número de funcionários1599
Tipo de títulosDepository Receipt
Fim do ano fiscalJul 10
EndereçoLaarderhoogtweg 25
CidadeAMSTERDAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal1101 EB
Telefone31763030
Sitehttps://www.argenx.com/
Código da empresaARGX
Data de listagemJul 10, 2014
CEOvan Hauwermeiren (Tim)
Executivos da empresa argenx SE
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Pamela M. (Pam) Klein
Dr. Pamela M. (Pam) Klein
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel
General Counsel
--
--
Dr. Luc Truyen
Dr. Luc Truyen
Chief Medical Officer
Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Pamela M. (Pam) Klein
Dr. Pamela M. (Pam) Klein
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de argenx SE?
Os cinco principais acionistas de argenx SE são: Mr. Tim van Hauwermeiren
Quantas instituições possuem ações da argenx SE (ARGX)?
Em 2026Q1, 942 instituições possuíam ações da argenx SE, com valor de mercado aproximado de 31.47M, representando 50.86% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2793210.00.
